Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main Corvus Pharmaceuticals, Inc. Transaction History

Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main

$94.9 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2018 Aug 14, 2018	SELL	$9.42 - $13.73 $328,362 - $478,600	-34,858 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$7.48 - $11.53 $260,737 - $401,912	34,858 New	34,858 $402,000

Others Institutions Holding CRVS

# of Institutions

Shares Held

30.4M

Call Options Held

1.06M

Put Options Held

84.3K

Orbimed Advisors LLC San Diego, CA

6.94M
Shares

$33.3 Million
0.86% of portfolio
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct

5.56M
Shares

$26.7 Million
0.08% of portfolio
Samlyn Capital, LLC New York, NY

4.53M
Shares

$21.7 Million
0.39% of portfolio
Adams Street Partners LLC Chicago, IL

3.28M
Shares

$15.7 Million
10.6% of portfolio
Vanguard Group Inc Valley Forge, PA

2.42M
Shares

$11.6 Million
0.0% of portfolio

View Full List

About Corvus Pharmaceuticals, Inc.

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $223M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

More about CRVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main, based on Form 13F filings with the SEC.

News

Stay updated on Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main with notifications on news.

Account